<PAGE>
                                  FORM 1O-Q/A

                      SECURITIES AND EXCHANGE COMMISSION
                            Washington, D.C. 20549
(Mark One)

     [X]  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
     SECURITIES EXCHANGE ACT OF 1934
     For the quarterly period ended June 30, 1998

                                      OR

     [ ]  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
     SECURITIES EXCHANGE ACT OF 1934
     For the transition period from        to
                                    ------     ------
     Commission file number 0-19732
                            -------

                          CORVAS INTERNATIONAL, INC.
            (Exact name of Registrant as specified in its charter)

         DELAWARE                                       33-0238812
(State or other jurisdiction                        (I.R.S. Employer
of incorporation or organization)                   Identification No.)

                            3030 SCIENCE PARK ROAD
                          SAN DIEGO, CALIFORNIA 92121
             (Address of principal executive offices and zip code)

                                (619) 455-9800
             (Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act: None

Securities registered pursuant to Section 12(g) of the Act:

                        Common Stock, $0.001 par value
                               (Title of class)

     Indicate by check mark whether the Registrant (l) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
Registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days.

                           Yes  X    No
                              -----    -----

     At July 31, 1998, there were 15,085,575 shares of Common Stock, $0.001
par value, of the Registrant issued and outstanding.


<PAGE>


Item 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS


     As the Company announced on August 14, 1998, in the press release 
attached hereto as Exhibit 99.1, Schering Corporation ("Schering-Plough") and 
the Company have agreed to terminate their oral thrombin inhibitor 
collaboration.  As a result, the Company's potential future milestone 
payments and research and development funding under its existing 
collaborations will be reduced.

     Accordingly, the Company hereby amends its "Liquidity and Capital
Resources" subsection of its Management's Discussion and Analysis of Financial
Condition and Results of Operations, as follows:

     "If all the milestones on all of the Company's existing collaborations
are met, Corvas could receive a maximum of $69,931,000 in future milestone
payments and research and development funding over the next several years."



Item 6.  EXHIBITS AND REPORTS ON FORM 8-K

     a.  Exhibits

     EXHIBIT NUMBER                DESCRIPTION

           99.1                    Press Release dated August 14, 1998
                                   related to the termination of the oral
                                   thrombin inhibitor collaboration with
                                   Schering-Plough.


<PAGE>

                                  SIGNATURES



     Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned thereunto duly authorized.


                                       CORVAS INTERNATIONAL, INC.



Date: August 25, 1998                  By: /s/ RANDALL E. WOODS
                                           ---------------------------------
                                           Randall E. Woods
                                           President and Chief Executive Officer




Date: August 25, 1998                  By: /s/ CAROLYN M. FELZER
                                           ---------------------------------
                                           Carolyn M. Felzer
                                           Senior Director of Finance
                                           Principal Financial Officer